Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
213.17 USD | +0.44% | -0.21% | +65.94% |
Sep. 22 | Hawkish Remarks by Fed Officials Weigh on Equity Markets | MT |
Sep. 22 | Hawkish Remarks by Fed Officials Weigh on Equity Markets | MT |
Financials (USD)
Sales 2023 * | 2,407 M | Sales 2024 * | 3,184 M | Capitalization | 39 837 M |
---|---|---|---|---|---|
Net income 2023 * | -650 M | Net income 2024 * | -266 M | EV / Sales 2023 * | 15,9x |
Net cash position 2023 * | 1,498 M | Net cash position 2024 * | 1,885 M | EV / Sales 2024 * | 11,9x |
P/E ratio 2023 * | -62,6x | P/E ratio 2024 * | -152x | Employees | - |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -0.15% | ||
1 week | +2.83% | ||
Current month | +2.99% | ||
1 month | +2.90% | ||
3 months | +9.48% | ||
6 months | +4.54% | ||
Current year | +65.15% |
1 week
212.15
217.08

1 month
203.61
217.08

Current year
126.47
217.08

1 year
116.08
217.08

3 years
105.43
217.08

5 years
50.71
217.08

10 years
26.02
217.08

Managers | Title | Age | Since |
---|---|---|---|
David Epstein
CEO | Chief Executive Officer | 61 | Nov. 08 |
Roger Dansey
CTO | Chief Tech/Sci/R&D Officer | 67 | 2018 |
Todd Simpson
DFI | Director of Finance/CFO | 62 | 2005 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
CHM | Chairman | 54 | 2022 |
David Epstein
BRD | Director/Board Member | 61 | Nov. 08 |
Nancy Simonian
BRD | Director/Board Member | 62 | 2012 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.99% | 189 M$ | -5.94% | - | |
2.68% | 2 M$ | -0.04% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-29 | 213.27 | +0.49% | 580 610 |
23-09-28 | 212.24 | -0.15% | 1,299,094 |
23-09-27 | 212.55 | -1.67% | 3,383,466 |
23-09-26 | 216.16 | +0.30% | 2,974,834 |
23-09-25 | 215.52 | +0.85% | 1,876,335 |
Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT
More quotes
Seagen Inc. specializes in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Net sales break down by source of income as follows:
- product sales (88%);
- royalties (9.6%);
- licenses and collaboration agreements (2.4%).
Calendar
2023-10-25
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
212.24USD
Average target price
225.41USD
Spread / Average Target
+6.21%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
+65.15% | 39 837 M $ | |
-44.18% | 38 162 M $ | |
-3.51% | 36 203 M $ | |
-6.84% | 34 219 M $ | |
-26.77% | 21 754 M $ | |
+27.20% | 20 298 M $ | |
-13.27% | 14 663 M $ | |
-17.93% | 10 763 M $ | |
-18.72% | 10 608 M $ | |
-10.37% | 10 014 M $ |